Melatonin suppresses the metastatic potential of osteoblastic prostate cancers by inhibiting integrin α₂ β₁ expression

Huai-Ching Tai^{1

2}, Shih-Wei Wang^{3

4

5}, Sanskruti Swain⁶, Liang-Wei Lin⁷, Hsiao-Chi Tsai^{8

9}, Shan-Chi Liu¹⁰, Hsi-Chin Wu^{10

11

12}, Jeng-Hung Guo^{7

13}, Chun-Lin Liu^{7

13}, Yu-Wei Lai^{14

15}, Tien-Huang Lin^{16

17}, Shun-Fa Yang^{18

19}, Chih-Hsin Tang^{6

7

8

20

21}

Affiliations

¹ School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
² Department of Urology, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan.
³ Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
⁴ Institute of Biomedical Sciences, Mackay Medical College, Taipei, Taiwan.
⁵ Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁶ International Master Program of Biomedical Sciences, China Medical University, Taichung, Taiwan.
⁷ Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
⁸ Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan.
⁹ Department of Internal Medicine, Division of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan.
¹⁰ Department of Medical Education and Research, China Medical University Beigang Hospital, Beigang, Yunlin, Taiwan.
¹¹ Department of Urology, China Medical University Hospital, Taichung, Taiwan.
¹² Department of Urology, China Medical University Beigang Hospital, Beigang, Yunlin, Taiwan.
¹³ Department of Neurosurgery, China Medical University Hospital, Taichung, Taiwan.
¹⁴ Division of Urology, Taipei City Hospital Renai Branch, Taipei, Taiwan.
¹⁵ Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
¹⁶ Department of Urology, Buddhist Tzu Chi General Hospital Taichung Branch, Taichung, Taiwan.
¹⁷ School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan.
¹⁸ Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
¹⁹ Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
²⁰ Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
²¹ Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan.

PMID: 35174530
DOI: 10.1111/jpi.12793

Melatonin suppresses the metastatic potential of osteoblastic prostate cancers by inhibiting integrin α₂ β₁ expression

Huai-Ching Tai et al. J Pineal Res. 2022 Apr.

. 2022 Apr;72(3):e12793.

doi: 10.1111/jpi.12793. Epub 2022 Mar 10.

Authors

Affiliations

¹ School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
² Department of Urology, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan.
³ Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
⁴ Institute of Biomedical Sciences, Mackay Medical College, Taipei, Taiwan.
⁵ Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
⁶ International Master Program of Biomedical Sciences, China Medical University, Taichung, Taiwan.
⁷ Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
⁸ Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan.
⁹ Department of Internal Medicine, Division of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan.
¹⁰ Department of Medical Education and Research, China Medical University Beigang Hospital, Beigang, Yunlin, Taiwan.
¹¹ Department of Urology, China Medical University Hospital, Taichung, Taiwan.
¹² Department of Urology, China Medical University Beigang Hospital, Beigang, Yunlin, Taiwan.
¹³ Department of Neurosurgery, China Medical University Hospital, Taichung, Taiwan.
¹⁴ Division of Urology, Taipei City Hospital Renai Branch, Taipei, Taiwan.
¹⁵ Department of Urology, College of Medicine and Shu-Tien Urological Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
¹⁶ Department of Urology, Buddhist Tzu Chi General Hospital Taichung Branch, Taichung, Taiwan.
¹⁷ School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan.
¹⁸ Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
¹⁹ Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
²⁰ Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
²¹ Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan.

PMID: 35174530
DOI: 10.1111/jpi.12793

Abstract

Advanced prostate cancer often develops into bone metastasis, which is characterized by aberrant bone formation with chronic pain and lower chances of survival. No treatment exists as yet for osteoblastic bone metastasis in prostate cancer. The indolamine melatonin (N-acetyl-5-methoxytryptamine) is a major regulator of the circadian rhythm. Melatonin has shown antiproliferative and antimetastatic activities but has not yet been shown to be active in osteoblastic bone lesions of prostate cancer. Our study investigations reveal that melatonin concentration-dependently decreases the migratory and invasive abilities of two osteoblastic prostate cancer cell lines by inhibiting FAK, c-Src, and NF-κB transcriptional activity via the melatonin MT₁ receptor, which effectively inhibits integrin α₂ β₁ expression. Melatonin therapy appears to offer therapeutic possibilities for reducing osteoblastic bone lesions in prostate cancer.

Keywords: MT1 receptor; bone metastasis; integrin; melatonin; osteoblastic prostate cancer.

PubMed Disclaimer

References

REFERENCES

1. Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378(7):645-657.
1. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005;65(17):7554-7560.
1. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006;12(20 Pt 2):6213s-6216s.
1. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer. 2010;116(6):1406-1418.
1. Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18(9):533-548.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Melatonin suppresses the metastatic potential of osteoblastic prostate cancers by inhibiting integrin α₂ β₁ expression

Affiliations

Melatonin suppresses the metastatic potential of osteoblastic prostate cancers by inhibiting integrin α₂ β₁ expression

Authors

Affiliations

Abstract

References

REFERENCES

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous